New Launch11 Dec 2025, 10:19 am
Suven Life Sciences Achieves 100% Patient Enrolment Milestone in Phase-2b Clinical Trial of Ropanicant for MDD, Ahead of Schedule
AI Summary
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, has successfully achieved its 100% patient enrolment milestone in the Phase-2b clinical trial of Ropanicant, a nicotinic a482 receptor antagonist for treating Major Depressive Disorder (MDD). The study, conducted exclusively in the USA, enrolled 195 patients in less than six months. The company anticipates topline data readout by May 2026.
Key Highlights
- Phase-2b study is a randomized, double-blind, placebo-controlled trial with 195 patients across 35 sites in the USA.
- Study evaluates the efficacy and safety of Ropanicant in patients with MDD, compared to placebo.
- 100% patient enrolment milestone achieved more than two months ahead of schedule.
- No significant safety concerns observed to date.
- Topline efficacy and safety results expected in May 2026.